Edgestream Partners L.P. Buys Shares of 8,391 Natera, Inc. (NASDAQ:NTRA)

Edgestream Partners L.P. acquired a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,391 shares of the medical research company's stock, valued at approximately $1,187,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CWM LLC grew its stake in shares of Natera by 13.6% in the 1st quarter. CWM LLC now owns 25,778 shares of the medical research company's stock worth $3,645,000 after buying an additional 3,077 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Natera by 6.2% in the 1st quarter. Arizona State Retirement System now owns 36,209 shares of the medical research company's stock valued at $5,120,000 after purchasing an additional 2,124 shares in the last quarter. Berbice Capital Management LLC raised its holdings in shares of Natera by 38.6% in the 1st quarter. Berbice Capital Management LLC now owns 1,525 shares of the medical research company's stock valued at $216,000 after purchasing an additional 425 shares in the last quarter. Xponance Inc. raised its holdings in shares of Natera by 41.3% in the 1st quarter. Xponance Inc. now owns 22,562 shares of the medical research company's stock valued at $3,190,000 after purchasing an additional 6,591 shares in the last quarter. Finally, Cerity Partners LLC raised its stake in shares of Natera by 7.3% during the 1st quarter. Cerity Partners LLC now owns 85,645 shares of the medical research company's stock worth $12,111,000 after acquiring an additional 5,863 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on NTRA shares. UBS Group increased their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Barclays increased their target price on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Piper Sandler raised their price objective on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Finally, Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and an average price target of $184.63.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $4.48 during trading hours on Friday, reaching $138.90. The stock had a trading volume of 1,384,580 shares, compared to its average volume of 1,415,107. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The firm's 50 day moving average is $160.09 and its 200-day moving average is $158.02. The stock has a market capitalization of $18.97 billion, a price-to-earnings ratio of -94.49 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. Natera's revenue for the quarter was up 36.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.56) earnings per share. Analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In other news, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director directly owned 8,118 shares in the company, valued at $1,358,628.48. This trade represents a 34.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $150.12, for a total value of $450,360.00. Following the sale, the insider owned 136,205 shares of the company's stock, valued at approximately $20,447,094.60. This represents a 2.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,272 shares of company stock valued at $8,345,368 over the last ninety days. 7.60% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.